All In Biotech

Drug Trial Radar · NCT00155389

Community-based Helicobacter Pylori Eradication

Community-based Helicobacter Pylori Eradication With Two Sequential Antibiotic Regimens for the Residents and Migrants From a High-risk Area for Gastric Cancer

Last checked: Nov 19, 2026Latest source record: Nov 14, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

5,000

Planned (sponsor's estimate)

Start

Jan 2004

Primary completion

Dec 2015

Study completion Dec 2015

Sponsor

Lead sponsor
National Taiwan University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Based on a universal eradication of H. pylori in an offshore island (Matsu) with a high prevalence of gastric cancer as well as premalignant gastric lesion, we first examined the infection rate of H. pylori. Secondly, we evaluated the efficacy of clarithromycin-based triple therapy with a levofloxacin-based rescue treatment. And thirdly, we tested the hypothesis that whether the cure of H. pylori can reverse the premalignant gastric lesion. Fourth, we determine the cost-effectiveness of this intervention. The gene-environment interaction will be addressed regarding gastric cancer carcinogenesis. Finally, the incident rate of gastric cancer would be followed in this cohort.

Conditions

  • Helicobacter Pylori Infection

Interventions

  • Helicobacter pylori eradicationDrug

    For subjects who received the first-line treatment, the costs included the initial 13C-UBT, one-week triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and clarithromycin 500mg twice daily), and the confirmatory 13C-UBT. For subjects in whom the initial treatment failed, the costs further included the re-treatment consisting of ten-day triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and levofloxacin 500mg once daily), and the confirmatory 13C-UBT. The first round of study was between 2004 and 2005, the second round was between 2008 and 2009, and the third round was between 2012 and 2013.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Successful helicobacter eradication, change in premalignant gastric lesion, and change in gastric cancer incidence rateTime frame: 12 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Lee Yi-Chia

    Taipei, Taiwan · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.